NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) has been awarded first place in the Healthcare category at the BOLD Awards VII, held on March 27, 2026, in Barcelona. The award recognizes the company's leadership in developing exosome-based therapies for central nervous system (CNS) injuries. This accolade underscores the potential of NurExone's proprietary platform and its lead product, ExoPTEN, which has shown promising preclinical results for treating acute spinal cord and optic nerve injuries.
The BOLD Awards honor organizations that demonstrate boldness and innovation in their respective fields. Being selected by a panel of global industry leaders highlights the significance of NurExone's approach to regenerative medicine. The company's focus on exosome-based therapies offers a novel method for delivering therapeutic payloads to damaged CNS tissues, potentially overcoming limitations of traditional treatments.
In conjunction with the award, NurExone announced its intention to engage Investor Brand Network (IBN), subject to TSX Venture Exchange approval. The engagement, effective April 1, 2026, aims to bolster investor awareness through distribution of news and corporate updates across more than 5,000 outlets. The one-year agreement, with a monthly fee of $6,500, is designed to strengthen market visibility and support long-term shareholder value. IBN's broad reach and specialized communications platforms are expected to help NurExone reach a wider audience of investors and stakeholders.
The importance of this announcement extends beyond the award itself. For NurExone, gaining recognition from a prestigious organization like BOLD Awards validates its scientific and strategic direction. The company's lead candidate, ExoPTEN, has received Orphan Drug Designation from regulatory authorities, facilitating a clearer pathway to clinical trials in the United States and Europe. This regulatory milestone, combined with strong preclinical data, positions NurExone to potentially address significant unmet medical needs in CNS injuries, where few effective treatments exist.
Additionally, the engagement with IBN reflects a proactive approach to investor relations. By leveraging IBN's network, which includes wire solutions, editorial syndication, and social media distribution, NurExone aims to ensure that its progress and milestones are effectively communicated to the investment community. This is particularly crucial for biotech companies, where scientific advancements must be translated into shareholder value.
The BOLD Awards victory also serves as a third-party endorsement of NurExone's technology. It may attract further interest from potential partners, collaborators, and investors who seek innovative therapies in the regenerative medicine space. The award, combined with the company's strategic communications efforts, could enhance NurExone's profile in the competitive biotech landscape.
NurExone has established a U.S. subsidiary, Exo-Top, to anchor its North American operations. This subsidiary is expected to play a key role in the company's growth strategy, as it aims to commercialize its exosome-based delivery system and potentially offer solutions to other companies interested in quality exosomes and targeted delivery for various indications.
In summary, the BOLD Awards recognition and the planned engagement with IBN mark important steps for NurExone as it advances its pipeline and seeks to build investor confidence. The company's focus on exosome-based therapies for CNS injuries addresses a critical area of unmet need, and the award highlights its potential to make a significant impact in the field of regenerative medicine.
